Roche reports pivotal MS win, but deaths add to safety questions
A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis (RMS) has hit its primary endpoint, positioning…
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according…
Roche pill succeeds in another MS study, but approval questions linger
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…